AI prediction technology for better targeted patient selection in clinical trials
– Automated prediction of clinical progression based on patient’s MRI and clinical data
– Robust algorithms pre-trained on large US/EU databases – optimizable using data from a specific clinical trial
– Adjustable selection sensitivity for an optimal trade-off between screening cost & success likelihood
– Automated reporting with easily interpretable results
AI prediction technology for better targeted patient selection in clinical trials
– Automated prediction of clinical progression based on patient’s MRI and clinical dataimaging markers
– Robust algorithms pre-trained on large US/EU databases – optimizable using data from a specific clinical trial
– Adjustable selection sensitivity for an optimal trade-off between screening cost & success likelihood
– Automated reporting with easily interpretable results
BENEFITS
selection of the patients with higher risk of clinical decline↓
more targeted patient sample
↓
increase probability of clinical trial success*
selection of the patients with higher risk of clinical decline
→
more targeted patient sample
→
increase probability of clinical trial success*
Qynapse is a medical technology company that unlocks the potential of quantitative imaging and AI to optimize diagnosis, prognosis and longitudinal monitoring of patients with neurological diseases.
